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A B S T R A C T
Purpose: Doxorubicin, as an eﬀective chemotherapeutic drug, is commonly used for combating various solid and
hematological tumors. However, doxorubicin-induced cardiotoxicity is considered as a serious adverse eﬀect,
and it limits the clinical use of this chemotherapeutic drug. The use of melatonin can lead to a decrease in the
cardiotoxic eﬀect induced by doxorubicin. The aim of this review was to evaluate the potential role of melatonin
in the prevention of doxorubicin-induced cardiotoxicity.
Methods: This review was conducted by a full systematic search strategy based on PRISMA guidelines for the
identiﬁcation of relevant literature in the electronic databases of PubMed, Web of Science, Embase, and Scopus
up to January 2019 using search terms in the titles and abstracts. 286 articles were screened in accordance with
our inclusion and exclusion criteria. Finally, 28 articles were selected in this systematic review.
Results: The ﬁndings demonstrated that doxorubicin-treated groups had increased mortality, decreased body
weight and heart weight, and increased ascites compared to the control groups; the co-administration of mel-
atonin revealed an opposite pattern compared to the doxorubicin-treated groups. Also, this chemotherapeutic
agent can lead to biochemical and histopathological changes; as for most of the cases, these alterations were
reversed near to normal levels (control groups) by melatonin co-administration. Melatonin exerts these pro-
tection eﬀects through mechanisms of anti-oxidant, anti-apoptosis, anti-inﬂammatory, and mitochondrial
function.
Conclusion: The results of this systematic review indicated that co-administration of melatonin ameliorates the
doxorubicin-induced cardiotoxicity.
1. Introduction
After cardiovascular diseases, cancer is considered as the second
cause of death in the world [1]. According to a recent report on global
cancer incidence and mortality, it was estimated 18.1 million new
cancer cases and 9.6 million deaths from cancer in the world in 2018
[2]. Also, a rapidly growing cancer incidence and mortality has been
reported worldwide [2]. There are several modalities for cancer treat-
ment including surgery, radiation therapy, chemotherapy, etc. [3].
Chemotherapy, as a systemic therapeutic modality, is eﬀectively used
for the treatment of various cancers; however, its clinical utility is re-
stricted due to a wide range of adverse eﬀects on normal cells and
tissues [4,5].
Doxorubicin (Adriamycin), as an eﬀective chemotherapeutic drug,
is commonly applied since the late 1960s against solid tumors such as
breast, lung, testicular, thyroid, ovarian cancers, and hematological
tumors of Hodgkin Lymphoma, and non-Hodgkin lymphomas [6,7].
The immediate side eﬀects of this chemotherapeutic drug such as ar-
rhythmia, myelosuppression, nausea, and vomiting are reversible or
clinically manageable [7]. Nevertheless, cardiotoxicity induced by
doxorubicin is considered as a serious adverse eﬀect, and it limits the
clinical use of this chemotherapeutic drug; this side eﬀect can lead to
reduced quality of life and sometimes fatalities. In this regard, various
methods are proposed to decrease cardiotoxic eﬀect induced by dox-
orubicin [8,9].
When it is found that the formation of reactive oxygen species (ROS)
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can have an important eﬀect in the doxorubicin-induced cardiotoxic
mechanism by reducing indigenous anti-oxidant systems in the body,
the use of exogenous anti-oxidants was introduced [10,11]. Melatonin,
as an indole-derived hormone, is principally generated and secreted by
the pineal gland, and it has applied to protect against the oxidative
damage [12]. This hormone exerts an antioxidative eﬀect through two
direct and indirect mechanisms. The direct pathway of melatonin is
exerted mostly by formation of radical adduct, hydrogen transfer, and
single electron transfer. In another pathway (indirect), the anti-oxida-
tive eﬀects of this hormone can be exerted by stimulation of anti-oxi-
dant enzymes, protection of anti-oxidant enzymes against oxidative
damage, modulation of genomic expressions, etc. Furthermore, it has
been reported that oxidative stress has key role in triggering in-
ﬂammation and apoptosis, and melatonin with its anti-inﬂammatory
and anti-apoptotic properties can relieve these eﬀects [4,5].
In this study, a systematic search was performed on the role of
melatonin on doxorubicin-induced cardiotoxicity. In addition, it was
tried to answer the following issues: 1) the mechanisms underlying
doxorubicin-induced cardiotoxicity, 2) the role of melatonin in the
prevention of doxorubicin-induced cardiotoxicity, and 3) the mechan-
isms related to the preventive role of melatonin.
2. Methods
2.1. Search strategy
In the current study, a systematic search was done based on the
guideline of the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) [13]. Literature search was carried out to
assess all relevant studies in both medical subject heading (MeSH) or
advance on electronic databases including PubMed, Web of Science,
Embase, and Scopus up to January 2019 using the keywords “Mela-
tonin” AND “Doxorubicin” OR “Adriamycin” AND “Heart” OR “myo-
cardium” OR “Myocardial” OR “Cardiomyopathy” OR “Myocyte cardiac
muscle cell” OR “Cardiopathic” OR “Cardiopathy” OR “cardiotoxicity”
OR “cardiomyocyte” in title, abstract or keywords.
2.2. Study selection
The inclusion criteria considered in this systematic review were full-
text articles with (a) English language, (b) the aforementioned key
search, (c) adequate information, and (d) without restriction in pub-
lications with in-vivo or in-vitro. The exclusion criteria were (a) hemo-
dynamic studies, (b) poster, (c) not related paper, (d) case report, (e)
review paper, (f) editorials, and (g) letter to the editor.
2.3. Data extraction
Each eligible article was reviewed by two researchers and the fol-
lowing data were extracted: (a) author name and the year of publica-
tion; (b) models; (c) doxorubicin dosage and route of administration
type; (d) outcomes of doxorubicin on cardiac tissue; (e) melatonin do-
sage and route of administration; and (f) melatonin co-administration
outcomes.
3. Results
3.1. Literature search
The process of study selection is illustrated in the Fig. 1.
286 articles were obtained by searching on the above-mentioned
databases up to January 2019. After the screening articles, 243 of them
were excluded by investigating their titles and abstracts and 43 studies
were qualiﬁed for assessment of their full-text. Thereafter, the studies
inconsistent with inclusion criteria or the studies with missing in-
formation were omitted. Finally, 28 remaining articles were included in
this systematic review. A summary of the extracted data related to the
eligible studies is listed in the Table 1.
3.2. The protective role of melatonin against doxorubicin-induced
cardiotoxicity
3.2.1. Survival study
The ﬁndings showed that mortality in the groups treated by dox-
orubicin was signiﬁcantly higher than the control group
[14,15,23,29,31,36]. Furthermore, it has been reported that the sur-
vival rate after doxorubicin treatment in rats had a dose-dependent
manner [29]. Kim et al. [29] represented that the survival rates for
control, 5 mg/kg, 15 mg/kg, and 25 mg/kg doxorubicin groups were
100%, 100%, 85%, and 14%, respectively.
The use of melatonin signiﬁcantly attenuated doxorubicin-induced
mortality [14,15,23,29,31,36]; for instance, doxorubicin-induced mor-
tality decreased from 86% to 20% (P < 0.05) by melatonin treatment
[29]. Moreover, it was observed no diﬀerence between the control and
melatonin groups [29].
3.2.2. Body weight, heart weight, and ascites changes
According to the obtained results, it was revealed that the body
weight, heart weight and ratio of heart to the body weight of rats/mice
were decreased in the doxorubicin group than the control group
[14,15,18,20,23,29,41]. In addition, a signiﬁcant accumulation of as-
cites was reported in the rats treated with doxorubicin compared to the
control rats; the survival rate in the group with high ascites value was
signiﬁcantly higher than the other rats [14,15].
When both melatonin and doxorubicin was administered to the
rats/mice, it was found an increase in the body weight, heart weight
and ratio of heart to body weight compared to the doxorubicin-treated
group [14,15,18,41]. Administration of melatonin also resulted in a
signiﬁcant decrease of doxorubicin-induced ascites value [14,15].
3.2.3. Biochemical changes
The biochemical changes of heart tissue can be observed in the
doxorubicin-treated group, as listed in the Table 1. For example, the
malondialdehyde (MDA), 4-hydroxyalkenes (4-HDA), serum creatine
phosphokinase (CPK), serum creatine kinase, serum troponin I, leptin,
triglycerides, cholesterol, lactate dehydrogenase (LDH), serum aspar-
tate aminotransferase (AST), myocardial and plasma thiobarbituric acid
reactive substances (TBARS), creatine kinase isoenzyme (CK-MB), glu-
tamic-oxaloacetic acid transaminase (GOT), glutamic-pyruvic acid
transaminase (GPT) in plasma, plasma concentrations of transferrin,
ferritin, iron and protein carbonyl levels were increased signiﬁcantly in
the doxorubicin-treated group than the control group
[14–16,18–20,22,23,25–33,37,40]. In addition, blood and tissue glu-
tathione (GSH), superoxide dismutase (SOD), and Glutathione-S-
Transferase (GST) levels were decreased signiﬁcantly compared to the
control groups [16,19,25,28,30–32].
The ﬁndings showed that melatonin administration preserved dox-
orubicin-induced biochemical changes (for most of the cases)
[14–16,18,19,22,23,25–31,33,37,40].
3.2.4. Histological changes
The obtained results from histological evaluation of the doxor-
ubicin-treated groups revealed the following histological changes: cel-
lular edema, loss of myoﬁbril, swelling of mitochondria, vacuolization
of cytoplasm, dilation of sarcotubular system, decrease of β-adreno-
ceptor (BAR) density in cell membrane, increase of membrane perme-
ability of cultured neonatal myocytes, decrease of myocytes, decrease
of myocyte size, increase of mitochondrial ﬁssion (round-shaped mi-
tochondria), decrease of mitochondrial major/minor aspect ratio, ﬁbers
with dark acidophilic cytoplasm and pyknotic nuclei, disarrangement of
sarcomeres, disruption of microﬁlaments and Z-line, increase of number
and size of mitochondria, presence of oval-shaped cells with thin long
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processes, etc. (The rest of the histological changes is listed in the
Table 1) [14–16,18,19,22,23,25–31,33,37,40].
The results of most studies showed that co-administration of dox-
orubicin and melatonin resulted in the prevention of doxorubicin-in-
duced histological changes [14–16,18,19,22,23,25–31,33,37,40].
4. Discussion
In the present study, we aimed to review a serious adverse eﬀect
(cardiotoxicity) induced by doxorubicin as well as co-administration
eﬀects of melatonin on this disorder. Some of the important cardiac
complications induced by doxorubicin as well as the eﬀects of mela-
tonin on these adverse eﬀects are shown in the Fig. 2.
The cardiovascular system is one of the most important systems of
the body, and malfunction in this system strongly relates to patients'
morbidities, demanding huge cost consuming, and is considered as one
of the major reasons of mortality [42]. Most of the current literature
data indicate that melatonin in combination with chemotherapeutic
agents reduces the anti-cancer eﬀects of these agents in the cancerous
cells. Melatonin also provides beneﬁts in reduction of toxicity in the
normal cells [4,5]. To better understand this issue, it is reported that
formation of ROS can exert both positive and negative eﬀects on normal
and cancerous tissues. ROS have a positive role in signal transduction
and gene transcription while they may act as a trigger for carcinogen-
esis via persistent DNA injuries [43]. It is also reported that reduced
sensitivity and resistance of cancer cells to chemotherapeutic agents are
common, which may result from genomic instability of the malignant
cells. The researchers concluded that melatonin by its pleiotropic
property exerts eﬀects on sensitization of the cancer cells to the anti-
cancer agents viamodulating the expression and phosphorylation status
of drug targets, the reduced clearance of drugs by aﬀecting their me-
tabolism and transport within the body, decreased survival of malig-
nant cells via altering DNA repair and telomerase activity, and en-
hanced responses to cell death-associated mechanisms such as apoptosis
and autophagy [4,5].
The mechanistic eﬀects of doxorubicin on the cardiac cellular
pathway as well as the protective eﬀects of melatonin and its reported
mechanisms on doxorubicin-induced cardiotoxicity are discussed
below.
4.1. Anti-oxidant actions
It is well-known that free radicals are commonly produced in the
normal cells, and the cells have several defense mechanisms against
them [44]. In oxidative stress conditions, there is an imbalance between
the free radical amounts and anti-oxidant defense systems, causing an
elevation of free radicals [45,46]. The cardiotoxicity induced by dox-
orubicin mainly exerts its eﬀects through inhibiting the oxidative stress
defense systems and producing several more kinds of free radicals. The
free radicals attack cell macromolecules, resulting in their malfunction
[47,48]. Oxidative stress also relates strongly to many disorders in-
cluding cancers, neurotoxicity, aging, diabetes, etc. [49–51]. Further-
more, doxorubicin increases free radicals especially through impair-
ment of mitochondrial malfunction, as the main source of free radicals.
It is clearly demonstrated that free radicals are normally produced in
the cells, especially through electrons leakage from the mitochondrial
electron transport chain (ETC), and this process increases during mi-
tochondria injury [48]. O2− is one of the ROS molecules, which is
turned to H2O2 by SOD enzyme [52]. Furthermore, non-radical ROS
including H2O2 is produced during malfunction of mitochondrial
NADPH oxidases and transferred by aquaporins to the cytoplasm
[53,54]. H2O2 has several destinations: 1) CAT enzyme produces H2O
and O2 from H2O2 [55], 2) H2O2 through Fenton and Haber-Weiss Net
reactions produces OH [56], and 3) H2O2 via the activity of glutathione
peroxidase (GPx) enzyme and consuming GSH produces 2H2O [57].
Normally, there is a low amount of nitric oxide (NO) in the cardiac
cells, and doxorubicin increases its level. In this context, NO is known to
exert important roles in cellular signaling during pathological processes
Fig. 1. Flow diagram used in the present study for selection process.
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al
.,
20
03
[2
6]
In
vi
vo
/r
at
Si
ng
le
do
se
of
20
m
g/
kg
&
ip
↑M
D
A
,↑
M
or
ph
ol
og
ic
al
da
m
ag
e
(i
nﬂ
am
m
at
or
y
ce
ll
in
ﬁ
lt
ra
ti
on
&
m
yo
ca
rd
ia
l
ﬁ
br
os
is
)
4
m
g/
kg
&
1
h
be
fo
re
or
24
h
af
te
r
do
xo
ru
bi
ci
n
in
je
ct
io
n
fo
r
2
da
ys
&
ip
↓M
D
A
,↓
M
or
ph
ol
og
ic
al
da
m
ag
e
Ba
lli
et
al
.,
20
04
[2
7]
In
vi
vo
/r
at
Fo
ur
do
se
s
of
3
m
g/
kg
&
ip
↑M
D
A
,d
es
tr
uc
ti
on
of
m
yo
ﬁ
br
ils
,d
is
or
ga
ni
za
ti
on
of
sa
rc
om
er
es
,m
it
oc
ho
nd
ri
al
de
ge
ne
ra
ti
on
&
fo
rm
at
io
n
of
gi
an
t
m
it
oc
ho
nd
ri
a
&
lip
id
ac
cu
m
ul
at
io
n,
ac
cu
m
ul
at
io
n
of
ﬁ
la
m
en
to
us
st
ru
ct
ur
es
in
sa
rc
op
la
sm
,
st
ru
ct
ur
al
ch
an
ge
s
in
ca
pi
lla
ri
es
,↑
C
ol
la
ge
n
ﬁ
be
rs
fo
rm
in
g
bu
nd
le
s
6
m
g/
kg
/d
ay
&
3
h
be
fo
re
ea
ch
do
xo
ru
bi
ci
n
in
je
ct
io
n
&
ip
↓M
D
A
,p
re
se
rv
at
io
n
of
al
l
st
ru
ct
ur
al
ch
an
ge
s
A
hm
ed
et
al
.,
20
05
[2
8]
In
vi
vo
/r
at
Si
ng
le
do
se
of
15
m
g/
kg
&
ip
↑S
er
um
TP
I&
le
pt
in
,T
G
s
&
ch
ol
es
te
ro
l&
LD
L,
↓S
er
um
T3
&
T4
&
IL
-1
a,
↑M
D
A
&
N
O
,↓
SO
D
&
G
Px
&
C
A
T
le
ve
ls
5
m
g/
kg
/d
ay
&
fo
r
10
co
ns
ec
ut
iv
e
da
ys
st
ar
ti
ng
3
da
ys
be
fo
re
do
xo
ru
bi
ci
n
in
je
ct
io
n
&
ip
↓S
er
um
TP
I
&
le
pt
in
,T
G
s
&
ch
ol
es
te
ro
l
&
LD
L,
↑
Se
ru
m
T
3
&
T
4
&
IL
-1
a,
↓M
D
A
&
N
O
,↑
SO
D
&
G
Px
&
C
A
T
le
ve
ls
K
im
et
al
.,
20
05
[2
9]
In
vi
vo
/r
at
Si
ng
le
do
se
s
of
5,
15
,2
5
m
g/
kg
&
ip
↑M
or
ta
lit
y,
↓B
od
y
w
ei
gh
t,
m
it
oc
ho
nd
ri
al
sw
el
lin
g,
va
cu
ol
iz
at
io
n
of
cy
to
pl
as
m
,t
hi
nn
in
g
of
Z
lin
es
,l
os
s
of
m
yo
ﬁ
br
ils
,↓
C
el
l
le
ng
th
&
ar
ea
of
m
yo
cy
te
s,
co
m
et
-
lik
e
m
or
ph
ol
og
y,
↑D
N
A
m
ig
ra
ti
on
di
st
an
ce
↑M
D
A
&
LD
H
,↑
Se
ru
m
cr
ea
ti
ne
ki
na
se
10
m
g/
kg
/d
ay
&
1
h
be
fo
re
do
xo
ru
bi
ci
n
in
je
ct
io
n
an
d
ev
er
y
12
h
th
er
ea
ft
er
fo
r
6
da
ys
&
sc
↓M
or
ta
lit
y,
re
gu
la
r
m
yo
ﬁ
br
ill
ar
ar
ra
ng
em
en
ts
,
pr
es
er
ve
d
m
it
oc
ho
nd
ri
a,
no
rm
al
le
ng
th
of
Z
lin
e,
re
st
or
at
io
n
of
ce
ll
le
ng
th
,↓
D
N
A
da
m
ag
e,
pr
ev
en
te
d
D
N
A
m
ig
ra
ti
on
di
st
an
ce
,↓
M
D
A
&
LD
H
,↓
se
ru
m
cr
ea
ti
ne
ki
na
se
In
vi
vo
/r
at
Si
ng
le
do
se
of
45
m
g/
kg
&
iv
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
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Ta
bl
e
1
(c
on
tin
ue
d)
A
ut
ho
r
&
ye
ar
M
od
el
s
D
ox
or
ub
ic
in
do
sa
ge
&
ro
ut
e
of
ad
m
in
is
tr
at
io
n
ty
pe
O
ut
co
m
es
of
do
xo
ru
bi
ci
n
on
ca
rd
ia
c
ti
ss
ue
M
el
at
on
in
do
sa
ge
&
pr
ot
oc
ol
of
us
ag
e
&
ro
ut
e
of
ad
m
in
is
tr
at
io
n
M
el
at
on
in
co
-a
dm
in
is
tr
at
io
n
ou
tc
om
es
O
z
et
al
.,
20
06
[3
0]
↑M
D
A
,↓
G
SH
,↑
Se
ru
m
cr
ea
ti
ne
ki
na
se
,↑
Se
ru
m
A
ST
,
ce
llu
la
r
ed
em
a,
m
it
oc
ho
nd
ri
al
de
fo
rm
at
io
n,
de
cr
ea
se
d
gl
yc
og
en
st
or
es
,d
is
or
de
re
d
m
yo
ﬁ
br
ill
ar
y
st
ru
ct
ur
es
10
m
g/
kg
&
on
ce
a
da
y
fo
r
7
da
ys
be
fo
re
or
af
te
r
do
xo
ru
bi
ci
n
in
je
ct
io
n
&
sc
↓M
D
A
,↑
G
SH
,↓
Se
ru
m
C
PK
-M
B,
↓S
er
um
A
ST
,
pr
es
er
va
ti
on
of
ce
llu
la
r
st
ru
ct
ur
es
O
th
m
an
et
al
.,
20
08
[3
1]
In
vi
vo
/r
at
Si
ng
le
do
se
of
10
m
g/
kg
&
ip
↑M
or
ta
lit
y
ra
te
,↑
C
K
-M
B
&
LD
H
&
G
O
T
&
G
PT
in
pl
as
m
a,
↑P
la
sm
a
le
ve
ls
of
tr
an
sf
er
ri
n
&
fe
rr
it
in
&
ir
on
,
↑T
BA
R
S
&
PC
le
ve
ls
,↑
C
A
T
&
G
Px
,↓
G
ST
&
G
SH
15
m
g/
kg
/d
ay
&
5
da
ys
be
fo
re
an
d
5
da
ys
af
te
r
do
xo
ru
bi
ci
n
in
je
ct
io
n
&
ip
↓M
or
ta
lit
y
ra
te
,↓
C
K
-M
B
&
LD
H
&
G
O
T
&
G
PT
in
pl
as
m
a,
↓P
la
sm
a
le
ve
ls
of
tr
an
sf
er
ri
n
&
fe
rr
it
in
&
ir
on
,↓
TB
A
R
S
&
PC
le
ve
ls
,↓
C
A
T
&
G
Px
,↑
G
ST
&
G
SH
A
yd
em
ir
et
al
.,
20
10
[3
2]
In
vi
vo
/r
at
Si
ng
le
do
se
of
15
m
g/
kg
&
ip
↑T
is
su
e
TB
A
R
S,
↓S
O
D
,↑
Ti
ss
ue
C
A
T
5
m
g/
kg
/d
ay
&
fo
r
tw
o
co
ns
ec
ut
iv
e
da
ys
be
fo
re
do
xo
ru
bi
ci
n
in
je
ct
io
n
pl
us
on
ﬁ
rs
t
da
y
an
d
th
en
a
da
ily
in
je
ct
io
n
si
x
co
ns
ec
ut
iv
e
da
ys
↓T
is
su
e
TB
A
R
S,
↑S
O
D
O
zt
ur
k
et
al
.,
20
11
[3
3]
In
vi
vo
/r
at
Si
ng
le
do
se
of
20
m
g/
kg
&
ip
↑M
D
A
,↓
SO
D
&
G
Px
, ↑
Se
ru
m
C
K
-M
B,
pr
es
en
ce
of
ce
ll
in
ﬁ
lt
ra
ti
on
,s
in
gl
e
ﬁ
be
r
ne
cr
os
is
,i
nt
er
st
it
ia
l
ed
em
a,
di
so
rg
an
iz
at
io
n
of
m
us
cl
e
ﬁ
be
rs
&
va
cu
ol
iz
at
io
n
20
m
g/
kg
/d
ay
&
tw
ic
e
da
ily
,3
6
h
be
fo
re
an
d
co
nt
in
ue
d
fo
r
72
h
af
te
r
do
xo
ru
bi
ci
n
in
je
ct
io
n
&
po
↓M
D
A
,↑
SO
D
an
d
G
Px
,↓
Se
ru
m
C
K
-M
B,
no
ne
cr
ot
ic
ar
ea
s
or
ce
ll
in
ﬁ
lt
ra
ti
on
,h
is
to
lo
gi
c
pr
ot
ec
ti
on
of
ca
rd
ia
c
ti
ss
ue
Sa
g
et
al
.,
20
11
[3
4]
In
vi
tr
o/
m
yo
cy
te
10
μm
ol
/L
↑I
nt
ra
ce
llu
la
r
R
O
S,
↓I
nt
ra
ce
llu
la
r
C
a
tr
an
si
en
t
am
pl
it
ud
e,
↑D
ia
st
ol
ic
in
tr
ac
el
lu
la
r
C
a
le
ve
l,
↑D
ia
st
ol
ic
SR
C
a
lo
ss
,↓
SR
C
a
co
nt
en
t,
↑C
aM
K
II
ph
os
ph
or
yl
at
io
n
10
0
μm
ol
/L
↓D
ia
st
ol
ic
in
tr
ac
el
lu
la
r
C
a
le
ve
l,
↓D
ia
st
ol
ic
SR
C
a
lo
ss
,↑
SR
C
a
co
nt
en
t
A
ri
f
et
al
.,
20
13
[3
5]
In
vi
tr
o/
m
yo
cy
te
&
ﬁ
br
ob
la
st
0.
6–
10
μM
↓C
el
lv
ia
bi
lit
y,
↓N
um
be
r
of
in
ta
ct
sa
rc
om
er
es
,↓
C
yc
lin
D
1
le
ve
l,
↓E
xp
re
ss
io
n
of
pr
oc
ol
la
ge
n
by
ﬁ
br
ob
la
st
s
1
pM
,1
nM
,1
μM
&
12
h
pr
io
r
to
tr
ea
tm
en
t
↓V
ia
bi
lit
y
of
ﬁ
br
ob
la
st
s
Zh
an
g
et
al
.,
20
13
[3
6]
In
vi
vo
/r
at
Se
ve
n
do
se
s
of
2.
5
m
g/
kg
&
ip
↓S
ur
vi
va
l
ra
te
,↑
LP
O
,↓
SO
D
&
G
Px
,c
ha
ng
in
g
in
sh
ap
es
,s
iz
es
&
w
ei
gh
ts
of
he
ar
ts
(c
on
ge
st
ed
&
sw
ol
le
n,
w
it
h
in
cr
ea
se
d
vo
lu
m
es
&
vi
si
bl
e
pe
te
ch
ia
e
on
pe
ri
ca
rd
iu
m
),
m
yo
ca
rd
ia
l
in
ju
ri
es
10
m
g/
kg
/d
ay
&
on
ce
a
da
y
fo
r
a
to
ta
lo
f
15
ti
m
es
be
fo
re
do
xo
ru
bi
ci
n
in
je
ct
io
n
&
ip
↑S
ur
vi
va
lr
at
e,
↓L
PO
,↑
SO
D
&
G
Px
,n
or
m
al
sh
ap
es
of
he
ar
ts
w
it
h
m
ild
co
ng
es
ti
on
&
w
it
ho
ut
vi
si
bl
e
pe
te
ch
ia
e
on
pe
ri
ca
rd
iu
m
,a
lle
vi
at
io
n
of
m
yo
ca
rd
ia
l
in
ju
ri
es
Bi
lg
in
og
lu
et
al
.,
20
14
[3
7]
In
vi
vo
/r
at
C
um
ul
at
iv
e
do
se
of
18
m
g/
kg
(d
ox
or
ub
ic
in
in
je
ct
io
n
on
5t
h,
6t
h
an
d
7t
h
da
ys
)
&
ip
↑C
K
&
C
K
-M
B
&
cT
nT
&
LD
H
&
A
ST
,↓
SO
D
&
G
Px
,↑
M
D
A
,↑
TG
s
&
LD
L
&
V
LD
L,
↓H
D
L
10
m
g/
kg
/d
ay
fo
r
7
da
ys
&
ip
↓C
K
&
C
K
-M
B,
LD
H
&
A
ST
&
cT
nT
,↑
SO
D
&
G
Px
,↓
M
D
A
,↓
TG
s
&
LD
L
&
V
LD
L,
↑H
D
L
A
se
ns
io
-L
óp
ez
et
al
.,
20
16
[3
8]
In
vi
tr
o/
H
L-
1
ca
rd
io
m
yo
cy
te
5
μM
↑R
O
S,
↑R
es
ti
ng
C
a2
+
le
ve
l,
↓C
a2
+
pe
ak
am
pl
it
ud
e,
↑
D
C
F
ac
cu
m
ul
at
io
n,
↓M
it
oc
ho
nd
ri
al
m
em
br
an
e
po
te
nt
ia
l
10
0
m
M
&
1
h
af
te
r
do
xo
ru
bi
ci
n
tr
ea
tm
en
t
↓R
O
S,
↓R
es
ti
ng
C
a2
+
le
ve
l,
↑C
a2
+
pe
ak
am
pl
it
ud
e,
↓
D
C
F
ac
cu
m
ul
at
io
n
Y
as
si
en
&
El
sa
id
,
20
17
[3
9]
In
vi
vo
/r
at
Fo
ur
do
se
s
of
3
m
g/
kg
&
ip
Fi
be
rs
w
it
h
da
rk
ac
id
op
hi
lic
cy
to
pl
as
m
&
py
kn
ot
ic
nu
cl
ei
,↑
A
po
pt
os
is
,
di
la
ta
ti
on
of
ve
ss
el
s
w
it
h
m
on
on
uc
le
ar
ce
llu
la
r
in
ﬁ
lt
ra
ti
on
s
&
de
po
si
te
d
co
lla
ge
n
ﬁ
be
rs
,
di
sa
rr
an
ge
m
en
t
of
sa
rc
om
er
es
,
di
sr
up
ti
on
of
m
ic
ro
ﬁ
la
m
en
ts
&
Z-
lin
e,
↑N
um
be
r
&
si
ze
of
m
it
oc
ho
nd
ri
a,
di
la
te
d
SE
R
&
T
tu
bu
le
s,
pr
es
en
ce
of
ov
al
sh
ap
ed
ce
lls
w
it
h
th
in
lo
ng
pr
oc
es
se
s
6
m
g/
kg
/d
ay
&
1
da
y
be
fo
re
do
xo
ru
bi
ci
n
in
je
ct
io
n
fo
r
15
da
ys
an
d
3-
h
be
fo
re
ea
ch
do
xo
ru
bi
ci
n
in
je
ct
io
n
&
ip
Su
pp
re
ss
io
n
of
ca
rd
io
m
yo
pa
th
y
in
du
ce
d
by
do
xo
ru
bi
ci
n
Li
u
et
al
.,
20
18
[4
0]
In
vi
tr
o/
H
9c
2
ce
lls
&
in
vi
vo
/m
ou
se
1
μM
(f
or
in
vi
tr
o)
&
tw
o
do
se
s
of
20
m
g/
kg
(f
or
in
vi
vo
)
&
ip
↓C
el
l
vi
ab
ili
ty
,↑
R
O
S,
↓C
el
lu
la
r
A
TP
,↑
M
D
A
,
↑A
po
pt
ot
ic
in
de
x
(B
ax
,c
le
av
ed
ca
sp
as
e
3,
Bc
l2
),
in
hi
bi
ti
on
of
p-
A
M
PK
&
PG
C
1α
,↓
N
R
F1
&
U
C
P2
&
TF
A
M
10
0
μM
(f
or
in
vi
tr
o)
&
20
m
g/
kg
/d
ay
&
ev
er
y
da
y
fo
r
a
to
ta
lo
f
8
ti
m
es
an
d
1
da
y
be
fo
re
in
it
ia
ld
ox
or
ub
ic
in
in
je
ct
io
n
(f
or
in
vi
vo
)
&
ip
↑C
el
l
vi
ab
ili
ty
,
↓R
O
S,
↑C
el
lu
la
r
A
TP
,↓
M
D
A
,
↓A
po
pt
ot
ic
in
de
x
(B
ax
,c
le
av
ed
ca
sp
as
e
3,
Bc
l2
),
↑p
-
A
M
PK
&
PG
C
1α
&
N
R
F1
,
U
C
P2
&
TF
A
M
G
ov
en
de
r
et
al
.,
20
18
[4
1]
In
vi
tr
o/
H
9c
2
ce
lls
&
in
vi
vo
/r
at
3
μM
(f
or
in
vi
tr
o)
&
th
re
e
do
se
s
of
4
m
g/
kg
(f
or
in
vi
vo
)
&
ip
↓C
el
l
vi
ab
ili
ty
,↓
Bo
dy
&
he
ar
t
w
ei
gh
t,
↑C
le
av
ed
ca
sp
as
e-
3
&
cl
ea
ve
d-
PA
R
P,
↑P
in
k1
&
PA
R
K
IN
,↓
M
fn
2,
↑D
rp
1
&
hF
is
1,
↓P
G
C
-1
α
pr
ot
ei
n
&
SI
R
T1
,↑
M
it
oc
ho
nd
ri
al
ﬁ
ss
io
n
(r
ou
nd
-s
ha
pe
d
m
it
oc
ho
nd
ri
a)
,↓
M
it
oc
ho
nd
ri
al
m
aj
or
/m
in
or
as
pe
ct
ra
ti
o,
↑D
eg
re
e
of
m
it
oc
ho
nd
ri
al
br
an
ch
in
g,
↓A
TP
10
μM
(f
or
in
vi
tr
o)
&
6
m
g/
kg
/d
ay
&
ev
er
y
da
y
fo
r
a
to
ta
lo
f1
4
ti
m
es
an
d
af
te
r
tu
m
or
in
oc
ul
at
io
n
(f
or
in
vi
vo
)
&
po
↓C
el
ld
ea
th
,↑
St
ro
ke
vo
lu
m
e,
↑H
ea
rt
w
ei
gh
t,
↓T
um
or
vo
lu
m
e,
↓C
le
av
ed
ca
sp
as
e-
3
&
cl
ea
ve
d-
PA
R
P,
↓
Pi
nk
1,
↑M
fn
1
&
M
fn
2,
↓↑
D
rp
1
&
hF
is
1,
↑P
G
C
-1
α
pr
ot
ei
n
&
SI
R
T1
,↓
M
it
oc
ho
nd
ri
al
ﬁ
ss
io
n,
↑
M
it
oc
ho
nd
ri
al
m
aj
or
/m
in
or
as
pe
ct
ra
ti
o,
↓D
eg
re
e
of
m
it
oc
ho
nd
ri
al
br
an
ch
in
g,
↑A
TP
↑,
in
cr
ea
se
;↓
,d
ec
ea
se
;&
,a
nd
;i
p,
in
tr
ap
er
it
on
ea
l;
iv
,i
nt
ra
ve
no
us
;s
c,
su
bc
ut
an
eo
us
;p
o,
pe
r
os
;M
D
A
,m
al
on
di
al
de
hy
de
;N
O
,n
it
ri
c
ox
id
e;
G
Px
,g
lu
ta
th
io
ne
pe
ro
xi
da
se
;T
BA
R
S,
th
io
ba
rb
it
ur
ic
ac
id
re
ac
ti
ve
su
bs
ta
nc
es
;G
SH
,
gl
ut
at
hi
on
e;
SO
D
,s
up
er
ox
id
e
di
sm
ut
as
e;
C
A
T,
ca
ta
la
se
;G
ST
,g
lu
ta
th
io
ne
S-
tr
an
sf
er
as
e;
LP
O
,l
ip
id
pe
ro
xi
da
ti
on
;L
D
H
,l
ac
ta
te
de
hy
dr
og
en
as
e;
G
O
T,
gl
ut
am
ic
ox
al
oa
ce
ta
te
tr
an
sa
m
in
as
e;
A
ST
,a
sp
ar
ta
te
am
in
ot
ra
ns
fe
ra
se
;
C
PK
,c
re
at
in
e
ph
os
ph
ok
in
as
e;
PA
R
P,
po
ly
(A
D
P-
ri
bo
se
)
po
ly
m
er
as
e;
4-
H
D
A
,4
-h
yd
ro
xy
al
ke
na
l;
LD
L,
lo
w
de
ns
it
y
lip
op
ro
te
in
;H
D
L,
hi
gh
de
ns
it
y
lip
op
ro
te
in
;V
LD
L,
ve
ry
lo
w
de
ns
it
y
lip
op
ro
te
in
;I
L,
in
te
rl
eu
ki
n;
C
K
-M
B,
cr
ea
ti
ne
ki
na
se
-m
yo
ca
rd
ia
lb
ou
nd
;G
PT
,g
lu
ta
m
at
e
py
ru
va
te
tr
an
sa
m
in
as
e;
C
K
,c
re
at
in
e
ki
na
se
;A
TP
,a
de
no
si
ne
tr
ip
ho
sp
ha
te
;T
PI
,t
ro
po
ni
n
I,
TG
s,
tr
ig
ly
ce
ri
de
s;
PC
,p
ro
te
in
ca
rb
on
yl
;M
fn
;m
it
of
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[58,59]. Interaction of NO with O2− produces ONOO− that is a po-
tential free radical [60]. The ONOO− can turn to NO2−, NO3−, OH−,
and CO3−. Thus, O2− can induce production of reactive nitrogen spe-
cies (RNS). It is demonstrated that doxorubicin via increasing the oxi-
dative stress and decreasing the activity of poly (ADP-ribose) poly-
merase (PARP) activity induces DNA damage. Doxorubicin increases
lipid peroxidation (LPO) markers including MDA, 4-HDA, and TBARs,
resulting in the cell membrane devastation and malfunctions [61,62].
In this condition, extracellular ions, especially Ca2+, easily enter the
cells and lead to the cell dysfunction and apoptosis [63]. Moreover,
peroxyl radical, as the production of LPO, worsens the oxidative stress
[64].
Melatonin or some of its metabolites have a strong anti-oxidant role.
Melatonin through its small size and amphiphilic property easily passes
into the cell and performs its pleiotropic eﬀect at both lipid and water
conditions [4,5]. It is also reported the anti-oxidant potential of mela-
tonin is several times more than the well-known antioxidants [65].
Generally, melatonin through both direct and indirect anti-oxidant
properties reduces cellular oxidative stress. Melatonin donates an
electron to neutralize free radicals in a direct way. Melatonin can
perform such action possibly via radical adduct formation, single elec-
tron transfer, and hydrogen atom transfer [66]. The possible mechan-
isms for melatonin's indirect way are via interaction with calmodulin,
which is involved in inhibition of nuclear RAR-related orphan receptor
alpha (RORa) receptor, epigenetic mechanisms, and modulating func-
tion or expression of Nuclear factor erythroid 2–related factor 2 (Nrf2)
[67,68]. Nrf2 acts as a transcription factor for several molecules which
are involved in an anti-oxidant activity, such as NAD(P)H Quinone
Dehydrogenase 1, heme oxygenase 1 (HO-1), GST, c-glutamylcysteine
synthase, and γ-glutamylcysteine synthetase (γ-GCS) [69]. Interaction
between each molecule of melatonin with two HO− produces cyclic 3-
hydroxymelatonin (3-OHM) which is oxidized to N1-acetyl-N2-formyl-
methoxykynuramne (AFMK). AFMK converts to N2-acetyl-5-methox-
ykynuramine (AMK) through a deformation process. Moreover, it is
worth-noting that 3-OHM, AFMK, and AMK also have anti-oxidant
properties [70]. GSH is an important intracellular anti-oxidant agent
that plays a primary role against oxidative stress [71]. GPx is another
anti-oxidant enzyme which turns H2O2 to 2H2O, and lipid peroxides to
lipid alcohols. By activity of GPx, two molecules of GSH in its thiol's
sulfur atom are oxidized into one glutathione disulﬁde (GSSG) [72].
GSH is recycled through reduction of GSSG by glutathione reductase
(GR) enzyme through consuming NADPH as a co-factor which is turned
to NADP+ [73]. As mentioned, doxorubicin decreases heart GSH and
GR activity, which are both modiﬁed by melatonin. Melatonin would
do such action through its anti-oxidant activity, its synergistic eﬀects
with other anti-oxidants agents, up-regulation of GSH, and elevation of
g-glutamylcysteine production [74]. Melatonin via its pleiotropic eﬀect
inhibits elevation of NO and RNS induced by doxorubicin [4,5]. Mel-
atonin through its anti-oxidant eﬀect and elevation of PARP enzyme
activity decreases doxorubicin-induced DNA damage [75].
Previous studies have clearly and strongly mentioned that there is a
relation between the elevation of oxidative stress with the initiation of
inﬂammation and apoptosis pathway [76,77].
4.2. Anti-apoptotic actions
Apoptosis is a physiological pathway that regulates cell death and
has critical roles in homeostasis and cell survival. Apoptosis is needed
to eliminate the harmed or transformed cells; this is required for
shaping the organs or controlling the cell numbers [78]. Any irregu-
larity or reduction of this pathway could induce tissue disorders or
cancer [79,80]. Doxorubicin-induced cardiomyocyte apoptosis as a
pathogenic mechanism in acute cardiotoxicity [46,81] and mitochon-
drial-dependent intrinsic apoptosis are the major reasons for cardiac
dysfunction [82]. Elevation of mitochondrial transition pore opening
(mPTP) and mitochondrial membrane permeabilization (MMP) con-
stitutes an essential step of the intrinsic pathway leading to apoptosis
[83]. In addition, cardiotoxicity of doxorubicin occurs possibly due to
the inducible eﬀect of free radicals-induced on opening of mPTP. It is
demonstrated that free radicals are involved in mitochondrial damage
and protein oxidation, leading to irreversible formation of large holes in
the inner membrane, the so-called permeability transition causing loss
of MMP. It has been reported that aglycone metabolites of doxorubicin
increase Ca2+-dependent permeability of the inner mitochondrial
membrane to small solutes [84], which is accompanied by the release of
mitochondrial Ca2+, mitochondrial swelling, and the collapse of the
membrane potential. Doxorubicin also causes alterations in calcium
homeostasis which may accelerate through the chance of opening of
Fig. 2. The molecular mechanisms of cardiac cyto-
toxicity-induced by doxorubicin. Doxorubicin in-
duces oxidative stress mostly through mitochondrial
dysfunction. Also, doxorubicin through inhibition of
SOD, GST, and GSH enzymes induces increasing free
radicals and elevation in LPO markers. Furthermore,
doxorubicin elevates apoptosis through reduction in
BCL-2 and elevation of BAX activations as well as it
increases cytochrome C releases and caspase 3 levels.
In addition, this chemotherapeutic drug involves in
caspase independent apoptosis via reduction of PARP
cleavage. In this content, doxorubicin via up-reg-
ulation of SIRT1 and reduction in ATP and AMPK
levels induces apoptosis. Also, doxorubicin via up-
regulation of Mfn2, and elevation of Drp1 and hFis1
induces mitochondrial ﬁssion. Melatonin, through an
opposite pattern induced by doxorubicin, reduces
cardiac doxorubicin-induced cytotoxicity.
↑ increased by doxorubicin; ↓ decreased by doxor-
ubicin; SOD, superoxide dismutase; GST, glu-
tathione-S-transferase; GSH, glutathione; MDA,
malondialdehyde; 4-HDA, 4-hydroxyalkenes;
TBARS, thiobarbituric acid reactive substances;
PARP, poly (ADP-ribose) polymerase; Mfn2, mito-
fusin2; Drp1, dynamin-related protein1; hFis1,
human mitochondrial ﬁssion 1 protein; AIF,
Apoptosis Inducing Factor; AMPK, AMP-activated
protein kinase.
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sarcoplasmic reticulum calcium channels and inhibition of Na+/Ca2+
exchanger, thus inducing Ca2+overload of sarcoplasm and membrane
injury [39,85].
Several studies have indicated that melatonin exerts cardiac pro-
tection against apoptosis under above-mentioned diverse conditions
[86,87]. Melatonin markedly enhances anti-apoptotic Bcl2 protein level
and reduces pro-apoptotic proteins like Bax and caspase 3 in doxor-
ubicin-induced apoptosis [40]. PARP is a nuclear enzyme which is in-
volved in some of the cellular processes like programmed cell death and
DNA repair. Doxorubicin induces elevation activity of caspases 3 and 7,
and thus initiation of PARP cleavage [88–90]; these alterations are
modiﬁed by melatonin. Another pathway related to the anti-apoptotic
eﬀects of melatonin against doxorubicin-induced cardiotoxicity is
through AMPK/PGC1 pathway. Peroxisome proliferator-activated re-
ceptor gamma coactivator 1-alpha (PGC-1α), one of the transcriptional
co-activators, is a master regulator of mitochondrial biogenesis and
energy metabolism [91]. The diminished activity or expression of
PGC1α is a usual sign of cardiac dysfunction [92]. The studies have
demonstrated that doxorubicin reduces the activity and expression of
PGC1α in cardiomyocytes thus worsening acute cardiotoxicity [93,94].
However, in-vivo and in-vitro studies showed that melatonin markedly
increases PGC1α expression [95]. 5′ AMP-activated protein kinase
(AMPK) has the main role in cell growth and survival via several me-
chanisms including protein synthesis, mitochondrial biogenesis, and
energy homeostasis in the heart. AMPK activation occurs by phos-
phorylation of Thr172 site, and this activation maintains myocytes'
energy balance [96]. It has been demonstrated AMPK's activity sig-
niﬁcantly reduces during doxorubicin-induced cardiotoxicity [97].
However, melatonin administration can eﬀectively reverse reduction of
AMPK, and down-regulation of PGC1α expression induced by doxor-
ubicin, thereby diminishing cardiomyocyte apoptosis [98]. Further-
more, anti-apoptotic property of melatonin is exerted via inhibiting
nuclear and mitochondrial DNA damage, prevention of mPTP and di-
rect modulation of diﬀerent proteins involved in the cell death related
processes [99]. These ﬁndings are further conﬁrmed by the fact that
mitochondrial membrane potential is restored by melatonin as a potent
anti-oxidant. The protective eﬀects of melatonin against doxorubicin-
induced loss of MMP may occur by inhibition of apoptosis and main-
tenance of mitochondria anti-oxidant capacity [24].
4.3. Anti-inﬂammatory actions
The inﬂammatory process is a biological phenomenon occurring in
response to harmful stimuli. The rate of inﬂammatory response must be
in balance, which is for reducing the harm of hazardous stimuli.
Inﬂammation is identiﬁed through elevation in leukocyte migration to
injured area, enhanced production of pro-inﬂammatory cytokines, and
increased chemotaxis of leukocytes [4,5]. Doxorubicin can induce heart
inﬂammation during chemotherapy. It has been previously mentioned
that oxidative stress induced by doxorubicin is involved in LPO and
may induce activation of lysosomal enzymes, and thereby promoting
inﬂammation in heart tissue. It is well-known that ROS take roles for
activation of NF-kappaB and IκB via IκB kinase (IKK). Inhibitory pro-
teins of kB family (IkB) hinder nuclear translocation of NF-kappaB. IKK
activation induces phosphorylation of IKB and NF-KB. Inactivation of
phosphorylated IKB promotes nuclear translocation of phosphorylated
NF-KB and its attachment to genomic promoter of numerous in-
ﬂammatory mediators. Several studies revealed that the use of doxor-
ubicin induces up-regulation of pro-inﬂammatory cytokines including
TNF-α, cyclooxygenase-2 (COX-2), intercellular adhesion molecule-1
(ICAM-1) and IL-6 [100–102]. Melatonin is reported to reduce oxida-
tive stress and activation of NF-KB as well as upregulation of in-
ﬂammatory cytokines [103]. ICAM-1 is a surface protein that exerts
important role in the inﬁltration of leucocytes to the damaged areas of
heart tissue [104].
In histological studies, it has been demonstrated that doxorubicin-
induced inﬁltration of inﬂammatory cells is reduced by melatonin.
4.4. Mitochondrial actions
The main site for the production of melatonin in organisms is mi-
tochondria [105]. Serotonin N-acetyltransferase (SNAT) is an enzyme
synthesizes melatonin, produced by cell genomic and translocated to
mitochondria matrix and intermembrane. Moreover, it is assumed that
melatonin production mainly occurs in matrix of mitochondria [106].
On a molecular level, the mitochondrial disorder is an apparent sign
of doxorubicin-induced cardiotoxicity. The selective removal of da-
maged mitochondria is called mitophagy, a process responsible for se-
lective degradation of mitochondria by autophagy, which is a necessary
process to keep mitochondrial quality control and cellular homeostasis
[107]. PARKIN and Pink1 are two vital proteins involved in mitophagy.
Pink1 binds to defected mitochondria and cytosolic PARKIN to initiate
mitophagic elimination [108]. It has been reported that in doxorubicin-
treated rats, the level of Pink1 protein signiﬁcantly increases in the
heart tissue. Furthermore, PARKIN protein level signiﬁcantly increased
in response to doxorubicin treatment. However, other studies have in-
dicated that melatonin elevates mitophagy and preserves mitochondrial
homeostasis [109]. Mitochondrial fusion in mammalian cells is con-
trolled by mitofusin (Mfn) proteins including Mfn1 and Mfn2. Mfn fa-
cilitates the binding of two separate mitochondria during early stages of
mitochondrial fusion [110]. Mitochondrial ﬁssion is controlled via dy-
namin-related protein1 (Drp) and hFis1 (human mitochondrial ﬁssion 1
protein); hFis1 is located in the outer mitochondrial membrane, and it
forms protein-protein interaction sites, which are protruding toward the
cytosol [111]. Drp1 is mainly located in the cytosol, and upon ﬁssion
Drp1 is recruited to the mitochondria via hFis1. When Drp1 interacts
with hFis1 at ﬁssion sites, a collar around the mitochondrion is formed.
The constriction of collar leads to a separation of the outer mitochon-
drial membrane, yielding two independent organelles [112]. Thus, the
results indicated that doxorubicin induces mitochondrial ﬁssion and
disrupting mitochondrial fusion via diminishing Mfn1 and Mfn2 ex-
pression as well as increasing mitochondrial ﬁssion protein (Drp1 and
hFis1) expression. Melatonin reversed the changes in expression of
mitochondrial ﬁssion and fusion proteins, favoring mitochondrial fu-
sion during doxorubicin-induced cardiotoxicity. In the cardiac cells,
mitochondrial ﬁssion and fusion are critical processes, where the
morphology of mitochondria adapts to meet the high metabolic needs
of the heart.
As it has been reported mitochondria is the main source of ROS
production, which is detoxiﬁed by melatonin. AFMK is produced by
melatonin interaction with cytochrome C, and it acts as a carrier of
electron in mitochondria electron transport chain [106]. Cytochrome
P450 isoform B in mitochondria is responsible for metabolizing mela-
tonin to N-acetylserotonin, and it exerts important roles in the anti-
tumor eﬀects of melatonin [113]. Melatonin in normal cells has bene-
ﬁcial eﬀects, whereas in cancerous cells it increases apoptosis due to
increasing release of cytochrome C into the cytoplasm via elevated
activation of N-acetyl serotonin. As reported in several studies, mela-
tonin has protective eﬀects on mitochondrial injury in organisms. It is
demonstrated that melatonin preserves normal mitochondrial mor-
phology [106]. Moreover, the use of melatonin caused a remarkable
increase in cellular ATP levels in comparison with the doxorubicin-
treated group. Furthermore, melatonin treatment alone is able to
maintain cellular ATP at basal levels suggesting that melatonin has a
protective eﬀect on mitochondria during stressful conditions such as
doxorubicin-induced cardiotoxicity [39]. Melatonin would do such
actions possibly through inﬂuencing mitochondrial dynamics, including
blockade of mitochondrial ﬁssion and induction of mitochondrial fusion
[106]. Melatonin counteracts markedly inhibitory eﬀect of doxorubicin
on Mfn proteins. In addition, melatonin is found to reduce the expres-
sion of Drp1 and hFis1 proteins, which are both increased by doxor-
ubicin. It was reported that the level of Pink1 protein in the heart tissue
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markedly diminished by melatonin [41]. It was demonstrated electron
leakage is the main mechanism for ROS elevation [114]. Melatonin
upregulates gene expression and increases activities of uncoupling
proteins (UCPs). Melatonin accelerates the electron ﬂow in the ETC and
reduces the electron leakage, thereby avoiding ROS formation [115].
It is also likely that melatonin maintained cellular ATP levels by
reducing electron leakage from the ETC via modulation of uncoupling
protein activity and thereby limiting molecular damage to the ETC
[41]. The proposed mechanism for this is melatonin inducible eﬀect on
UCPs activities in the mitochondrial inner membrane. The activation of
UCPs induces transferring of protons from intermembrane space to the
matrix and can be used to produce ATP [116,117].
5. Perspective of future research
It is known the use of doxorubicin, as a chemotherapy agent, is an
important way to battle cancer, especially in the progressive stage.
However, this chemotherapy agent has harmful eﬀects on the normal
cells which limit its usage as an option for cancer treatment [118]. The
recent research on diﬀerent in-vivo or in-vitro models demonstrated that
some agents can decrease the non-speciﬁc side eﬀects related to che-
motherapy on normal cells and even potentiate the eﬀects of che-
motherapy agents on cancerous cells or decrease drug resistance [4,5].
This property could be very eﬀective and important during che-
motherapy which especially needs more research. Cardiac injury re-
lated to chemotherapy may be associated with the treatment strategy,
personal features such as individual rate of doxorubicin metabolisms, or
even functions of other tissues that are involved in excretion of dox-
orubicin [119,120].
It is of noting that oxidative stress is involved in the initiation and
progress of cancers, and that induction of oxidative stress is considered
as one of the main mechanisms of battling cancer cells. Non-speciﬁc
induction of oxidative stress may combat both cancer cells and normal
cells in the target cells or even non-target cells [121]. In this context, it
has previously been reported that melatonin can be served as both pro-
oxidant agent for combating cancer cells, and as an anti-oxidant to
reduce free radical accumulation in normal cells, thus it can be pro-
posed as a wonderful agent to use for patients receiving chemotherapy.
The dual melatonin role has also been proposed for targeting doxor-
ubicin-related inﬂammation and apoptosis. Sometimes the che-
motherapy process is the best and most eﬀective way for cancer treat-
ment, but the non-speciﬁc side eﬀects and toxic injury to normal cells
can be the main problems that limit chemotherapy treatment [4,5].
Doxorubicin-induced cardiotoxicity is common during chemotherapy of
other cancerous tissues, which are not related to heart [122]. Thus, it
seems necessary to discover some agents eﬀective for protection of
normal cells from the perilous eﬀect of doxorubicin.
As already stated, the use of melatonin, as an adjuvant treatment
alongside chemotherapy, has a double eﬀect, as it would decrease side
eﬀects induced by chemotherapy agents on the normal cells and in-
crease the pathway which leads to death of cancerous cells [123,124].
Previously, it has been demonstrated that melatonin reduces the toxic
eﬀect of doxorubicin on the cardiac cells, but it needs to discover the
role of co-treatment of melatonin on cardiac cancerous cells, and to
identify underlying mechanisms [68]. In the present study, it can be
understood that melatonin reduces doxorubicin-induced cardiotoxicity
mainly by decreasing the oxidative stress via its direct and indirect
antioxidant property [70]. The limitation of this study is that the results
were interpreted according to the studies performed on animal models.
Because sometimes ﬁndings are diﬀerent between the animal and clinic
studies, and thus further clinical studies are needed.
6. Conclusion
According to the results of the present study, it was found that co-
treatment of melatonin resulted a decrease in the rate of mortality, an
increase in the body weight and heart weight, and a decrease in the
ascites value compared to doxorubicin-treated groups. Co-administra-
tion of doxorubicin and melatonin also ameliorated the doxorubicin-
induced biochemical and histopathological changes (for most of the
cases) by mechanisms of anti-oxidant, anti-apoptosis, anti-in-
ﬂammatory, and mitochondrial function.
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